MedTrace Logo

Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia

NCT02478710 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-05-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if administering inhaled antibiotics directly into the lungs in conjunction with intravenous (IV) antibiotics leads to better outcomes and decreased recurrence of ventilator associated pneumonia (VAP) when compared to IV antibiotics alone.

Conditions

  • Pneumonia, Ventilator-Associated

Interventions

DRUG

Aerosolized Tobramycin or Vancomycin

Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.

DRUG

Aerosolized Placebo

Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.

Sponsors & Collaborators

  • Wright State University

    lead OTHER

Principal Investigators

  • John K. Bini, MD · Wright State University

  • Priti Parikh, PhD · Wright State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-02-28
Completion
2022-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02478710 on ClinicalTrials.gov